Pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound

Patent metadata

Field	Value
Publication number	US-10973807-B2
Application number	US-201716079589-A
Country	US
Kind code	B2
Filing date	Feb 28, 2017
Priority date	Mar 1, 2016
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

The present invention provides a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt of the compound. Specifically, the invention provides a pharmaceutical composition containing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof, and at least one water soluble filler. The pharmaceutical composition of the invention features a rapid dissolution and good stability.

First claim

We claim:

1. A pharmaceutical composition, comprising:
1) 10-20 wt % of 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof, having a particle size distribution range d(0.9) thereof less than 60 μm;
2) 30-80 wt % of lactose or mannitol;
3) optionally 5-50 wt % of pregelatinized starch;
4) 1-30 wt % of a disintegrant, wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose and crospovidone; and
5) 0.5-5 wt % of a lubricant, wherein the lubricant is at least one selected from the group consisting of magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, and talc.

2. The pharmaceutical composition according to claim 1 , wherein the composition is a tablet or a capsule.

3. A method of treating cancer, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 1 .

4. The method according to claim 3 , wherein the cancer is kidney cancer, gastrointestinal stromal tumor, colorectal cancer, or pancreatic neuroendocrine tumor.

5. A method of treating cancer, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 2 .

6. The method according to claim 5 , wherein the cancer is kidney cancer, gastrointestinal stromal tumor, colorectal cancer, or pancreatic neuroendocrine tumor.

7. A pharmaceutical composition according to claim 1 , wherein the composition has a dissolution rate such that at least 80% of the active ingredient is released from the pharmaceutical composition in 45 minutes when measured in a dissolution medium containing water at 37±0.5° C. and at a paddle speed of 50 rpm.

8. A method of treating cancer, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 7 .

9. The method according to claim 8 , wherein the cancer is kidney cancer, gastrointestinal stromal tumor, colorectal cancer, or pancreatic neuroendocrine tumor.

10. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, malate, hydrobromide, p-toluenesulfonate, methanesulfonate, sulfate, and ethanesulfonate.

Assignees

• Jiangsu Hengrui Medicine Co

Inventors

• Lu Yun
• Zhang Xinhua
• Wang Chenyang
• Liu Tonghui

Classifications

• A61K31/437 Primary

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K9/1623

  Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title